PE20160692A1 - Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos - Google Patents

Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos

Info

Publication number
PE20160692A1
PE20160692A1 PE2016000545A PE2016000545A PE20160692A1 PE 20160692 A1 PE20160692 A1 PE 20160692A1 PE 2016000545 A PE2016000545 A PE 2016000545A PE 2016000545 A PE2016000545 A PE 2016000545A PE 20160692 A1 PE20160692 A1 PE 20160692A1
Authority
PE
Peru
Prior art keywords
pyrido
pyrazine
carboxamides
treatment
neurodegenerative disorders
Prior art date
Application number
PE2016000545A
Other languages
English (en)
Inventor
Ravi Jagasia
Juergen Wichmann
Jens-Uwe Peters
Roland Jakob-Roetne
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20160692A1 publication Critical patent/PE20160692A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)

Abstract

La invencion se refiere a compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas de formula (I); en donde R1 es hidrogeno; R2 es hidrogeno, alquilo inferior, entre otros; R3 es halogeno, heteroarilo, entre otros. Son compuestos preferidos: 8-(4-clorofenil)-pirido[4,3-b]pirazin-2-carboxamida; 8-(4-(trifluorometil)-fenil)-pirido[4,3-b]pirazin-2-carboxamida; 8-bromo-N-(1-cianociclopropil)-pirido[4,3-b]pirazin-2-carboxamida, entre otros. Tambien se refiere a un proceso de sintesis y a una composicion farmaceutica del compuesto de formula (I). Dichos compuestos estimulan la neurogenesis a partir de celulas madres neurales (CMN), siendo utiles en el tratamiento de transtornos neurodegenerativos como enfermedad de Parkinson, enfermedad de Alzheimer, entre otros
PE2016000545A 2013-11-12 2014-11-07 Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos PE20160692A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192406 2013-11-12

Publications (1)

Publication Number Publication Date
PE20160692A1 true PE20160692A1 (es) 2016-07-28

Family

ID=49552255

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000545A PE20160692A1 (es) 2013-11-12 2014-11-07 Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos

Country Status (18)

Country Link
US (1) US9670206B2 (es)
EP (1) EP3068781B1 (es)
JP (1) JP6229056B2 (es)
KR (1) KR101861937B1 (es)
CN (1) CN105764901B (es)
AU (1) AU2014350371B2 (es)
CA (1) CA2929461A1 (es)
CL (1) CL2016001024A1 (es)
CR (1) CR20160142A (es)
EA (1) EA028940B1 (es)
HK (1) HK1223916A1 (es)
IL (1) IL244619A0 (es)
MA (1) MA39027B1 (es)
MX (1) MX2016006052A (es)
PE (1) PE20160692A1 (es)
PH (1) PH12016500605A1 (es)
UA (1) UA117041C2 (es)
WO (1) WO2015071178A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108430986B (zh) 2015-10-26 2021-08-31 拜耳作物科学股份公司 作为有害生物控制剂的稠合双环杂环衍生物
WO2020025517A1 (en) * 2018-07-31 2020-02-06 Merck Patent Gmbh Tlr7/8 antagonists and uses thereof
US20220204499A1 (en) 2019-02-26 2022-06-30 Bayer Aktiengesellschaft Condensed bicyclic heterocyclic derivatives as pest control agents
WO2020173860A1 (en) 2019-02-26 2020-09-03 Bayer Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7282506B2 (en) * 2004-08-03 2007-10-16 Serenex, Inc. 2,8-disubstituted naphthyridine derivatives
CN101356173B (zh) * 2005-11-11 2012-10-31 阿特纳赞塔里斯有限公司 新的吡啶并吡嗪和它们作为激酶调节剂的用途
AU2010221417A1 (en) 2009-03-02 2011-09-22 Sirtris Pharmaceuticals, Inc. 8-substituted quinolines and related analogs as sirtuin modulators
CN102459240A (zh) * 2009-04-22 2012-05-16 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的氮杂环丁烷基二酰胺
AU2011274787B2 (en) * 2010-07-07 2016-06-16 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN105163727B (zh) * 2013-05-03 2018-08-17 豪夫迈·罗氏有限公司 刺激神经发生的异喹啉衍生物
TWI529171B (zh) * 2013-07-29 2016-04-11 赫孚孟拉羅股份公司 １，７－萘啶衍生物

Also Published As

Publication number Publication date
JP6229056B2 (ja) 2017-11-08
WO2015071178A1 (en) 2015-05-21
CR20160142A (es) 2016-05-04
CN105764901B (zh) 2018-06-22
EA028940B1 (ru) 2018-01-31
UA117041C2 (uk) 2018-06-11
KR20160061427A (ko) 2016-05-31
HK1223916A1 (zh) 2017-08-11
US9670206B2 (en) 2017-06-06
PH12016500605A1 (en) 2016-06-13
CA2929461A1 (en) 2015-05-21
AU2014350371B2 (en) 2018-02-15
MX2016006052A (es) 2016-07-18
MA39027A1 (fr) 2018-05-31
CN105764901A (zh) 2016-07-13
CL2016001024A1 (es) 2016-11-18
EP3068781A1 (en) 2016-09-21
IL244619A0 (en) 2016-04-21
JP2016536320A (ja) 2016-11-24
EA201690971A1 (ru) 2016-08-31
MA39027B1 (fr) 2018-10-31
EP3068781B1 (en) 2017-12-20
KR101861937B1 (ko) 2018-05-28
US20160251355A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
PE20181289A1 (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
PE20160691A1 (es) Nuevos derivados de triazolo[4,5-d]pirimidina
SV2017005434A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201592146A1 (ru) Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам
MY175272A (en) Novel benzimidazole derivatives as ep4 antagonists
PE20151001A1 (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
ECSP15004780A (es) Antagonistas del receptor de 5–ht3
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
PE20160692A1 (es) Pirido[4,3-b]pirazin-2-carboxamidas como agentes neurogenicos para el tratamiento de trastornos neurodegenerativos
EA201790519A1 (ru) Терапевтические соединения в качестве ингибиторов рецептора орексина-1
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
TW201613890A (en) Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators
EA201790207A1 (ru) Новые замещенные пиримидиновые соединения
EA201891710A1 (ru) Терапевтические соединения
MX2016008536A (es) Derivados de fluoro-naftilo.
MX2014006433A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
TR201904514T4 (tr) Makrosiklik LRRK2 kinaz inhibitörleri.
MX2017001096A (es) Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo.
EA201691831A1 (ru) Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
EA201591021A1 (ru) 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.